One attractive therapeutic approach in development is active immunisation against methamphetamine; a successful vaccine would aid abstinence by sequestering the drug in the event of a relapse, minimising its pharmacological effects.
Small molecules like methamphetamine are invisible to the immune system, requiring conjugation to a T cell epitope to make them immunogenic; the peptidic nature of this carrier results in presentation of the MHC class II-antigen complex to the immune system, initiating antibody isotype switching from IgM to IgG, effecting a specific and long-lasting immune response. Vaccines against nicotine and cocaine have reached clinical trials, but candidates against methamphetamine are still in early stages of development. 10 One area of vaccine optimisation is the choice of adjuvant, which is used to enhance the local immune response by increasing (local) inflammation, stimulating antigen presenting cells and acting as a depot. 11 Aluminium hydroxide (alum) has been the historically dominant adjuvant, but alternatives are being pursued in an effort to improve safety, increase the strength of the immune response and to access alternative immune response profiles.
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Liposomes have been explored as vaccine delivery systems since 1974 13 and are currently at the forefront of vaccine research due to their ability to safely deliver both antigen and adjuvant in a versatile and readily-optimisable manner at relatively low cost. Monophosphoryl lipid A (MPLA) is the only non-alum adjuvant approved for use (in conjunction with alum) in both the US and Europe 14, 15 A detoxified derivative of bacterial lipopolysaccharide (LPS), MPLA is believed to enhance the immune system via a combination of mechanisms including agonism of toll-like receptor 4 (TLR4), which invokes a signal cascade that results in the production of proinflammatory cytokines 16 and antigen-specific effector CD4+ and memory CD8+ T cells. 17 Synthetic MPLA (also termed phosphorylated hexaacyl disaccharide, PHAD or glycopyranoside lipid A, GLA) has also more recently been investigated as an alternative to the multicomponent, potentially heterogeneous, bacteria-derived MPLA. 18 Direct comparison has shown enhanced results using the synthetic version, 19 which being homogeneous, allows for precise control over the vaccine components. MPLA has been incorporated into liposomes (L(MPLA)) where it has shown stronger immunostimulation than alum, and synthetic L(MPLA) has been applied to drugs of abuse vaccines, where it has successfully elicited high antibody titres against heroin. 20 Another class of molecular adjuvant under investigation in clinical trials is the Quillaja saponins, which effect immunostimulation by providing T cells with direct costimulatory signals; the aldehyde moieties they contain are believed to mimic carbonyl groups on the surface of antigen-presenting cells (APCs), forming Schiff bases with free lysine residues on the surface of T cells. 21 MPLA and saponins are complex small molecules and herein we propose that a readily synthetically accessible adjuvant, tucaresol, may be a suitable substitute. Tucaresol is an orally bioavailable aldehyde-containing immunopotentiator, whose application in vaccines has been primarily limited to systemic use to enhance DNA-based vaccines, 22 but when used as a local adjuvant it has demonstrated enhanced Th cell priming This journal is © The Royal Society of Chemistry 2014 compared to both alum and saponin Quil A. 23 Tucaresol has been shown to elicit both cellular and humoural responses, 22 with characteristics of both Th 1 and Th 2-type immunity; 24 we have proposed that this mixed response is ideal for drugs of abuse vaccines. 25 Despite tucaresol being identified as an immunopotentiatory agent two decades ago, its use in vaccines has not flourished. Although tucaresol stimulates T cells, it has not been directly associated with the antigen as part of the vaccine design, and is usually administered orally or in a separate injection. We envisaged that incorporation of tucaresol into liposomes would enhance immunopotentiation by recruiting the liposomes to the T cells, promoting uptake of the liposomes and thus the associated antigen. Modification of tucaresol via lipidation would generate an amphiphilic molecule capable of being incorporated into the lipid bilayer of liposomes. We proposed that esterification of the acid would be a facile method to achieve this and here provide the first reported example of a lipid analogue of tucaresol (lipid tucaresol, LT1, Figure 1 ). Another key variable in drugs of abuse vaccine design is the choice of hapten. Our best candidate for vaccination against methamphetamine is MH6-SH (Figure 2) . 26, 27 This hapten requires thiol conjugation to the appropriately-activated carrier protein since it contains a secondary amine that would be incompatible with conjugation using activated carboxylic acids. We have found acid hapten conjugations to give more robust, efficient conjugation than their thiol counterparts, with the added benefit that the hapten precursors are stable upon storage. We therefore designed MH6t-CO2H (2, Figure 2 ) as a new hapten, proposing that switching from a secondary to a tertiary amine should not have a significant impact on antibody production; elsewhere it has been shown that anti-methamphetamine antibodies can still be generated despite the larger perturbation of derivatising this amine to a tertiary amide. Having chosen our target adjuvant and hapten, lipid tucaresol LT1 was therefore synthesised in two steps from 4-(bromomethyl)-benzoic acid via esterification with 1-hexadecanol, followed by etherification with 2,6-dihydroxybenzaldehyde (Scheme 1a). MH6t-CO2H, 2 was synthesised from methamphetamine via alkylation of the amine followed by saponification of the ester (Scheme 1b). /mL at 42 days) . The antibody concentration dropped throughout the study of MH6(SH)-KLH+SAS®, and given that our bleed was performed at a later time point, this may account for some of the discrepancy. Analysis of the ELISA data also shows a drop in antibody titre throughout this study rather than the expected increase after multiple boosts; it is likely that we used a suboptimal vaccination schedule as is can be seen that liposomal vaccination often requires larger spacing between boosts to promote the optimal response. In any case while there is scope for optimisation of the protocol, the direct comparison of MPLA and LT1, which was the primary goal of this study, clearly demonstrates the latter's efficacy as a synthetic adjuvant.
Additional scope for improvement of our [L(LT1)] vaccine should be achievable though optimisation of the vaccine composition. The concentrations of both MPLA and LT1 in this study were chosen based on previous work with MPLA. 19, 20 Tucaresol's effect on the immune response is known be concentration-dependent, with increasing immunopotentiation at lower doses, leading to immunosuppression at higher doses. 29 It is highly unlikely that the dose of LT1 used was optimal, and further investigation could result in significant improvement in the immune response. Finally, the location and length of the alkyl chain used for lipidation of tucaresol could also be optimised. In summary, we have synthesised the first lipid analogue of tucaresol, LT1, and shown that it is capable of eliciting an immune response against methamphetamine, demonstrating superior liposomal adjuvancy to MPLA and having great potential for future development. 
